×
About 671,298 results

Never Too Late: Smoking Cessation Just Before Lung Cancer Diagnosis Leads to Survival Benefit
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200126/full/

May 13th, 2020 - A retrospective study examining the time since a patient quit smoking before a lung cancer diagnosis and the subsequent survival outcomes after the lung cancer diagnosis indicated that it is never too late to stop smoking (Abstract 1512). Among patients diagnosed with lung cancer who had quit smoking within 2 years of lung cancer di...

Prolonged Opioid Use Associated With Reduced Survival After Lung Cance...
https://doi.org/10.1016/j.athoracsur.2020.09.015
The Annals of Thoracic Surgery; Chancellor WZ, Mehaffey JH et. al.

Nov 1st, 2020 - Lung cancer remains the leading cause of cancer death worldwide and the search for modifiable risk factors to improve survival is ongoing. There is a growing appreciation for a biological relationship between opioids and lung cancer progression. Our goal was to evaluate the association between perioperative opioid use and long-term survival after...

CASPIAN Update Shows Ongoing Survival Benefit With Durvalumab in ES-SCLC
https://www.targetedonc.com/view/caspian-update-shows-ongoing-survival-benefit-with-durvalumab-in-es-sclc

May 30th, 2020 - Updated findings from the phase 3 CASPIAN trial presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program showed maintained overall survival (OS) benefit of durvalumab (Imfinzi) treatment in combination with platinum etoposide chemotherapy in newly diagnosed patients with extensive-stage small cell lung cancer (ES-SCLC) after more than 2 years o...

Will DFS Benefit Translate Into Survival Benefit in ADAURA?
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200221/full/

Jun 24th, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

Combined First-Line Treatment With Ipilimumab, Nivolumab, Limited Chemotherapy Prolongs Survival in Advanced NSCLC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200203/full/

May 30th, 2020 - Positive findings from the CheckMate 9LA study position nivolumab/ipilimumab in combination with short-course chemotherapy as a new first-line treatment option for metastatic or recurrent non–small cell lung cancer (NSCLC) regardless of PD-L1 expression (Abstract 9501).

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer
https://www.onclive.com/conference-coverage/asco-2020/frontline-durvalumab-maintains-os-benefit-in-updated-essclc-findings

May 30th, 2020 - The addition of durvalumab (Imfinzi) to standard chemotherapy continued to demonstrate an improvement in overall survival (OS) for patients with treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), according to updated results from the phase 3 CASPIAN study presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer
https://ascopost.com/news/may-2020/first-line-pembrolizumab-plus-etoposideplatinum-for-extensive-stage-small-cell-lung-cancer/

May 30th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a near significant level vs placebo plus etoposide/platinum in patients with extensive-s...

Radiation or Surgery in Early Lung Cancer: Does It Make a Difference?
https://www.medpagetoday.com/hematologyoncology/lungcancer/94701

Sep 24th, 2021 - Long-term survival was equivalent for patients with early-stage non-small-cell lung cancer (NSCLC) whether treated with stereotactic ablative radiotherapy (SABR) or surgery, according to updated results from a prospective study. In an analysis of an additional 80 patients with medically operable, stage IA NSCLC treated with SABR, the overall survival (OS) rate was 91...

Targeted Therapy Drives Improves Outcomes Throughout Lung Cancer Subtypes
https://www.onclive.com/view/targeted-therapy-drives-improves-outcomes-throughout-lung-cancer-subtypes

Oct 6th, 2021 - The availability of targeted agents for patients with advanced non–small cell lung cancer (NSCLC) who harbor mutations in EGFR, RET, MET, and KRAS has not only led to improved outcomes, but provided greater flexibility for treatment-naïve and pretreated populations, with the possibility of enhanced intracranial activity, explained Pradnya Patil, MD, FACP, who added that such treat...

Forecasting lung cancer incidence, mortality, and prevalence to year 2030.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414713
BMC Cancer; Jakobsen E, Olsen KE et. al.

Sep 5th, 2021 - Lung cancer incidence and prevalence is increasing worldwide and there is a focus on prevention, early detection, and development of new treatments which will impact the epidemiological patterns of lung cancer. The clinical characteristics and the trends in incidence, mortality, and prevalence of lung cancer in Denmark from 2006 through 2015 are describ...

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Sm...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070549
Journal of Clinical Oncology : Official Journal of the Am... Johung KL, Yeh N et. al.

Oct 7th, 2015 - We performed a multi-institutional study to identify prognostic factors and determine outcomes for patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and brain metastasis. A total of 90 patients with brain metastases from ALK-rearranged NSCLC were identified from six institutions; 84 of 90 patients received radiotherapy to the brain (stereotactic radiosurgery [SRS] or...

Smoking cessation before lung cancer diagnosis linked to longer survival
https://www.healio.com/hematology-oncology/lung-cancer/news/online/{c987a307-b1e1-44ae-aae8-0d53228ea219}/smoking-cessation-before-lung-cancer-diagnosis-linked-to-longer-survival

May 13th, 2020 - People who quit smoking prior to a lung cancer diagnosis demonstrated considerably reduced risk for death due to all causes compared with those who continued to smoke, according to study results scheduled for presentation during the ASCO20 Virtual Scientific Program.

Association of computed tomography screening with lung cancer stage shift...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965744
BMJ (Clinical Research Ed.); Potter AL, Rosenstein AL et. al.

Apr 1st, 2022 - To determine the effect of the introduction of low dose computed tomography screening in 2013 on lung cancer stage shift, survival, and disparities in the stage of lung cancer diagnosed in the United States. Quasi-experimental study using Joinpoint modeling, multivariable ordinal logistic regression, and multivariable Cox proportional hazards modeling. US Nati...

The Survival Impact of Second Primary Lung Cancer in Patients With...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002287
Journal of the National Cancer Institute; Choi E, Luo SJ et. al.

Dec 12th, 2021 - Lung cancer survivors have a high risk of developing second primary lung cancer (SPLC), but little is known about the survival impact of SPLC diagnosis. We analyzed data from 138 969 patients in the Surveillance, Epidemiology, and End Results (SEER), who were surgically treated for initial primary lung cancer (IPLC) in 1988-2013. Each patient was...

MicroRNA signature predicts survival and relapse in lung cancer.
https://doi.org/10.1016/j.ccr.2007.12.008
Cancer Cell; Yu SL, Chen HY et. al.

Jan 3rd, 2008 - We investigated whether microRNA expression profiles can predict clinical outcome of NSCLC patients. Using real-time RT-PCR, we obtained microRNA expressions in 112 NSCLC patients, which were divided into the training and testing sets. Using Cox regression and risk-score analysis, we identified a five-microRNA signature for the prediction of treatment outcome of NSCLC in the training set. This ...

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung
https://doi.org/10.1016/S0140-6736(17)30565-2
Lancet (London, England); Hida T, Nokihara H et. al.

May 16th, 2017 - Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-001JP trial in Japanese patients with ALK-positive non-small-cell lung cancer. Given those promising results, we did a phase 3 trial to directly compare the efficacy and safety of alectinib and crizotinib. J-ALEX...

Survival After Adrenalectomy for Metastatic Lung Cancer.
https://doi.org/10.1245/s10434-021-11192-7 10.1001/jamaoncol.2015.0735 10.1016/j.lungcan.2014.07.020 10.1097/JTO.0000000000000673 10.1002/1097-0142(19900315)65:6<1318::AID-CNCR2820650611>3.0.CO;2-H 10.1016/S0003-4975(96)00611-X 10.1097/SLA.0000000000003876 10.1002/(SICI)1097-0142(19980115)82:2<395::AID-CNCR20>3.0.CO;2-T 10.1016/S0003-4975(00)02509-1 10.1016/j.lungcan.2005.02.012 10.1007/s00464-013-3274-z 10.1200/JCO.2007.14.2091 10.1002/cncr.29134 10.1200/JCO.1995.13.1.8 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X 10.1200/JCO.2016.34.15_suppl.100 10.1056/NEJMoa1507643 10.1056/NEJMoa1504627 10.1016/S0140-6736(15)01281-7 10.1016/S0140-6736(16)30958-8 10.1097/JTO.0b013e318171513b 10.1177/2324709617740909 10.1016/j.jtho.2015.09.009 10.1097/JTO.0000000000000133 10.1097/SLA.0000000000002749 10.1245/s10434-013-3050-2 10.1038/s41588-020-0628-z 10.1245/s10434-007-9520-7 10.1016/j.jss.2006.08.035 10.1007/s00268-014-2454-x 10.1007/s00262-018-2239-4 10.1186/s40425-016-0193-2
Annals of Surgical Oncology; Krumeich LN, Roses RE et. al.

Jan 7th, 2022 - Adrenal metastasectomy is associated with increased survival in non-small cell lung cancer (NSCLC) with isolated adrenal metastases. Although clinical use of adrenal metastasectomy has expanded, indications remain poorly defined. The aim of this study was to evaluate the clinical benefit of adrenal metastasectomy for all lung cancer subtypes. We performed a re...

Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit
https://www.onclive.com/conference-coverage/asco-2020/regardless-of-timing-smoking-cessation-before-lung-cancer-diagnosis-shows-survival-benefit

May 13th, 2020 - People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell ...
https://doi.org/10.1016/j.lungcan.2017.04.021
Lung Cancer (Amsterdam, Netherlands); Wakeam E, Acuna SA et. al.

Jun 5th, 2017 - The role of surgery in small cell lung cancer (SCLC) is controversial. Survival outcomes for resection of stage I-IIIA SCLC compared to chemotherapy-based non-surgical treatment (NST) were examined using propensity matching. 29,994 clinical stage I-IIIA SCLC patients, including 2,619 undergoing surgery, were identified in the National Cancer Database. Stage-specific ...

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Surviv...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815037
JAMA Jänne PA, van den Heuvel MM et. al.

May 12th, 2017 - There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer. To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib + docetaxel with docetaxel alone as a second-line therapy for advanced KRAS-mutant NSCLC. Multinational, rand...